Shikha Wadhwani

Phone+1 312 503 2167
Emailshikha.wadhwaninorthwesternedu

h-index
h10-index
h5-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

Training Experience

2011	Internship, Rush University Medical Center
2013	Residency, Rush University Medical Center
2016	Fellowship, Rush University Medical Center
2017	Fellowship, Ohio State University Medical Center

Education/Academic qualification

Clinical Research, MS, Rush Medical Collage

… → 2016

Medicine, MD, Rush Medical Collage

… → 2010

Research interests

Kidney

Fingerprint

Dive into the research topics where Shikha Wadhwani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

4 Finished
4 Active

Prot# VT-001-0050: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
Wadhwani, S.
Vera Therapeutics, Inc.
12/1/21 → 12/1/24
Project: Research project
Prot #Nef-301 OLE: An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IGA Nephropathy Who Have Completed Study Nef-301
Wadhwani, S.
Medpace Clinical Research LLC, Calliditas Therapeutics AB
5/7/21 → 5/27/24
Project: Research project
Cure GN 2.0 - UNC-PCC
Wadhwani, S.
University of North Carolina at Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases
8/16/19 → 5/31/24
Project: Research project
Protocol: Nef-301: A Randomzied, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary Iga Nephropathy at Risk Prgressing to End-Stage Renal Disease(NefIgArd)
Wadhwani, S.
Medpace Clinical Research LLC, Calliditas Therapeutics AB
2/5/19 → 1/20/23
Project: Research project
Prot: IM011073: A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis
Wadhwani, S.
Pharmaceutical Research Associates, Inc., Bristol-Myers Squibb Company
9/9/19 → 9/9/22
Project: Research project

8 Article
1 Letter
1 Review article

A Rare Case of Granulomatous Interstitial Nephritis in a Patient With COVID-19
Alotaibi, M., Ellis, C., Wadhwani, S. & Peleg, Y., 2022, In: Journal of Investigative Medicine High Impact Case Reports. 10
Research output: Contribution to journal › Article › peer-review

Open Access
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy
McGee, K., Stone, N. J., Wadhwani, S., Kanwar, Y. S., Villaflor, V. & Akhter, N., 2021, (Accepted/In press) In: Journal of Oncology Pharmacy Practice.
Research output: Contribution to journal › Article › peer-review
2 Scopus citations
A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease
Kitchlu, A., Jhaveri, K. D., Wadhwani, S., Deshpande, P., Harel, Z., Kishibe, T., Henriksen, K. & Wanchoo, R., Jan 2021, In: Kidney International Reports. 6, 1, p. 66-77 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
29 Scopus citations
Evaluation of the Reproductive Care Provided to Adolescent Patients in Nephrology Clinics: A Pediatric Nephrology Research Consortium Study
Pediatric Nephrology Research Consortium, May 2021, In: Kidney International Reports. 6, 5, p. 1411-1415 5 p.
Research output: Contribution to journal › Article › peer-review

Open Access

1 Scopus citations
Rituximab in fibrillary glomerulonephritis: Fumble or forward progress?
Wadhwani, S. & Jhaveri, K. D., 2021, In: Nephrology Dialysis Transplantation. 36, 1, p. 11-13 3 p.
Research output: Contribution to journal › Review article › peer-review

Shikha Wadhwani

Personal profile

Training Experience

Education/Academic qualification

Research interests

Fingerprint

Network

Dive into details

Prot# VT-001-0050: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)

Prot #Nef-301 OLE: An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IGA Nephropathy Who Have Completed Study Nef-301

Cure GN 2.0 - UNC-PCC

Protocol: Nef-301: A Randomzied, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary Iga Nephropathy at Risk Prgressing to End-Stage Renal Disease(NefIgArd)

Prot: IM011073: A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis

A Rare Case of Granulomatous Interstitial Nephritis in a Patient With COVID-19

A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy

A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease

Evaluation of the Reproductive Care Provided to Adolescent Patients in Nephrology Clinics: A Pediatric Nephrology Research Consortium Study

Rituximab in fibrillary glomerulonephritis: Fumble or forward progress?

Shikha Wadhwani

Personal profile

Training Experience

Education/Academic qualification

Research interests

Fingerprint

Network

Grants

Research Output